Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Mirabegron. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 known ✓ | P13945 | 18/20 | 1.00 |
| ▸ | ADRB1 | P08588 | 7/20 | 0.82 |
| ▸ | ADRB2 | P07550 | 7/20 | 0.82 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.57 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.57 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.57 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mirabegron SCHEMBL904789 | 1.00 | ADRB3 (1.00) | ADRB3ADRB1ADRB2CYP2D6SLC6A4 | |
| Mirabegron SCHEMBL805237 | 1.00 | ADRB3 (1.00) | ADRB3ADRB1ADRB2CYP2D6SLC6A4 | |
| Mirabegron SCHEMBL1405678 | 0.99 | ADRB3 (0.98) | ADRB3ADRB1ADRB2CYP2D6SLC6A4 | |
| Mirabegron SCHEMBL15993771 | 0.99 | ADRB3 (0.98) | ADRB3ADRB1ADRB2CYP2D6SLC6A4 | |
| Mirabegron SCHEMBL15993769 | 0.99 | ADRB3 (0.98) | ADRB3ADRB1ADRB2CYP2D6SLC6A4 | |
| Mirabegron SCHEMBL1509286 | 0.99 | ADRB3 (0.98) | ADRB3ADRB1ADRB2CYP2D6SLC6A4 | |
| Mirabegron SCHEMBL16611070 | 0.97 | ADRB3 (0.94) | ADRB3ADRB1ADRB2CYP2D6SLC6A4 | |
| SCHEMBL16609366 | 0.90 | ADRB3 (0.81) | ADRB3ADRB1ADRB2CYP2D6SLC6A4 | |
| SCHEMBL16609248 | 0.90 | ADRB3 (0.81) | ADRB3ADRB1ADRB2CYP2D6SLC6A4 | |
| SCHEMBL11914560 | 0.88 | ADRB3 (0.78) | ADRB3ADRB1ADRB2CYP2D6SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1481 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12638459-B2 | Method of diagnosing overactive bladder disorder | UNIVERSITY OF PORTSMOUTH HIGHER EDUCATION CORPORATION (GB) | 2026-05-26 | — | — | US | claimed |
| CN-122059833-A | Synthesis method of mirabegron key intermediate | 北京联本医药化学技术有限公司 | 2026-05-19 | — | — | CN | claimed |
| CN-122031433-A | Mirabegron sustained release preparation and preparation method thereof | 山东达因海洋生物制药股份有限公司 | 2026-05-15 | — | — | CN | claimed |
| US-12617809-B2 | Cardioprotective lipid and method of use | SIGNPATH PHARMA, INC. (US) | 2026-05-05 | — | — | US | claimed |
| US-20260115161-A1 | 2-HYDROXY-OCTADECENE-9-CIS-OATE FOR USE IN THE TREATMENT OF ONCOLOGICAL PATHOLOGIES AND NEUROPATHIC PAIN | LAMINAR PHARMACEUTICALS S A (ES) | 2026-04-30 | — | — | US | claimed |
| EP-4731194-A1 | MATERIALS AND METHODS FOR MITIGATING THE PRESENCE OF NITROSAMINES IN PACKAGING USING AN ACTIVE AGENT | CSP Technologies, Inc. (US) | 2026-04-29 | — | — | EP | claimed |
| US-20260108493-A1 | COMPOSITIONS COMPRISING A SEROTONERGIC TRYPTAMINE COMPOUND | CAAMTECH, INC. (US) | 2026-04-23 | — | — | US | claimed |
| US-12605340-B2 | Extended release composition of 2-(2-Aminothiazol-4-yl)-N-[4-(2{[(2R)-2-hydroxy-2-phenylethyl] amino} ethyl) phenyl] acetamide | ZIM LABORATORIES LIMITED (IN) | 2026-04-21 | — | — | US | claimed |
| EP-4724062-A2 | COMPOSITIONS AND METHODS FOR INCREASING EXPOSURE OF R(-)-MDA | EmpathBio, Inc. (US) | 2026-04-15 | — | — | EP | claimed |
| EP-4687805-A1 | MATERIALS AND METHODS FOR MITIGATING THE PRESENCE OF NITROSAMINES IN PACKAGING USING ACTIVATED CARBON OR A DERIVATIVE THEREOF | CSP Technologies, Inc. (US) | 2026-02-11 | — | — | EP | claimed |
| US-20100240697-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING OVERACTIVE BLADDER | ASTELLAS PHARMA INC. (JP) | 2010-09-23 | — | — | US | claimed |
| EP-2223690-A1 | PHARMACEUTICAL COMPOSITION FOR AMELIORATING LOWER URINARY TRACT SYMPTOM | Astellas Pharma Inc. (JP) | 2010-09-01 | — | — | EP | claimed |
| EP-2216021-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING OVERACTIVE BLADDER | Astellas Pharma Inc. (JP) | 2010-08-11 | — | — | EP | claimed |
| US-20080214633-A1 | Alpha-form or beta-form crystal of acetanilide derivative | ASTELLAS PHARMA INC. | 2008-09-04 | — | — | US | claimed |
| EP-1932838-A2 | Beta-form crystal of acetanilide derivative | Astellas Pharma Inc. (JP) | 2008-06-18 | — | — | EP | claimed |
| US-7342117-B2 | (R)-2-(2-aminothiazol-4-yl)-4'-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]-acetanilide; free base forms; stability; moisture resistance | ASTELLAS PHARMA INC. (JP) | 2008-03-11 | — | — | US | claimed |
| US-20050004190-A1 | Alpha-form or beta-form crystal of acetanilide derivative | ASTELLAS PHARMA INC. (JP) | 2005-01-06 | — | — | US | claimed |
| EP-1440969-A1 | ALPHA-FORM OR BETA-FORM CRYSTAL OF ACETANILIDE DERIVATIVE | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2004-07-28 | — | — | EP | claimed |
| CN-1136193-C | Imide derivatives or salts thereof | ֮����ҩ��ʽ���� | 2004-01-28 | — | — | CN | claimed |
| CN-1218045-A | Imide derivatives or salts thereof | YAMANOUCHI PHARMA CO LTD (JP) | 1999-06-02 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004190-A1 | Alpha-form or beta-form crystal of acetanilide derivative | IAPP, AMY1A, AMY2A | ADRB3 635/4885ADRB1 223/4885ADRB2 329/4885 |
| US-12617809-B2 | Cardioprotective lipid and method of use | TNNT2, CPT1B, TNNI3 | ADRB3 56/4885ADRB1 49/4885ADRB2 74/4885 |
| US-20100240697-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING OVERACTIVE BLADDER | BPHL, PDE12, UROD | ADRB3 23/4885ADRB1 36/4885ADRB2 17/4885 |
| US-20260108493-A1 | COMPOSITIONS COMPRISING A SEROTONERGIC TRYPTAMINE COMPOUND | ADRA2C, ADRB3, ADRA2B | ADRB3 2/4885ADRB1 4/4885ADRB2 6/4885 |
| US-12605340-B2 | Extended release composition of 2-(2-Aminothiazol-4-yl)-N-[4-(2{[(2R)-2-hydroxy-2-phenylethyl] amino} ethyl) phenyl] acetamide | ADRB2, ADRA2B, ADRB1 | ADRB3 4/4885ADRB1 3/4885ADRB2 1/4885 |
| US-12638459-B2 | Method of diagnosing overactive bladder disorder | P2RX5, CHRNA5, IL5 | ADRB3 131/4885ADRB1 46/4885ADRB2 59/4885 |
| US-20080214633-A1 | Alpha-form or beta-form crystal of acetanilide derivative | IAPP, AMY1A, AMY2A | ADRB3 760/4885ADRB1 249/4885ADRB2 351/4885 |
| US-20260115161-A1 | 2-HYDROXY-OCTADECENE-9-CIS-OATE FOR USE IN THE TREATMENT OF ONCOLOGICAL PATHOLOGIES AND NEUROPATHIC PAIN | PMP22, VHL, PAX8 | ADRB3 1058/4885ADRB1 2313/4885ADRB2 1077/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.